Current and Emerging Evidence for Toll-Like Receptor Activation in Sjögren's Syndrome.
Jeremy KiripolskyJill M KramerPublished in: Journal of immunology research (2018)
While the importance of Toll-like receptor (TLR) signaling is well established in many autoimmune diseases, the role of TLR activation in Sjögren's syndrome (SS) is poorly understood. Studies in mice and humans reveal that TLRs are potent mediators of inflammation in SS. TLRs are expressed and functional in salivary tissue, and TLRs in peripheral blood cells of SS patients are also upregulated and hyperresponsive to ligation. In this review, we will detail observations in mouse models regarding the importance of TLR activation in both local and systemic disease. We will then discuss studies in SS patients that provide evidence of the importance of TLR-mediated signaling in disease. While the ligands that activate TLRs in the context of SS are unknown, emerging data suggest that damage-associated molecular patterns (DAMPs) may be significant drivers of the chronic and unremitting inflammation that is characteristic of SS. We will discuss putative DAMPs that may be of clinical significance in disease. Therapies that target TLR signaling cascades will likely reduce both exocrine-specific and systemic manifestations of SS.
Keyphrases
- toll like receptor
- inflammatory response
- nuclear factor
- immune response
- end stage renal disease
- oxidative stress
- ejection fraction
- newly diagnosed
- peripheral blood
- chronic kidney disease
- mouse model
- induced apoptosis
- type diabetes
- peritoneal dialysis
- gene expression
- dna methylation
- adipose tissue
- rheumatoid arthritis
- genome wide
- systemic lupus erythematosus
- case report
- skeletal muscle
- patient reported outcomes
- metabolic syndrome
- insulin resistance
- electronic health record
- big data
- drug induced
- high fat diet induced
- artificial intelligence
- anti inflammatory